Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Equities

688621

CNE100005139

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-04-28 pm EDT 5-day change 1st Jan Change
57.69 CNY +1.51% Intraday chart for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. -2.88% -17.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(XSSC:688621) added to S&P Global BMI Index CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Beijing Langyan Life Technology Holdings Co., Ltd. from a group of shareholders. CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sun-Novo Pharma Gets License to Produce Kaneka’s Transdermal Patches MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sun-Novo Pharma Unit Gets Drug Regulator's Certification for Desmopressin Injection MT
Sun-Novo Pharma Unit to Set Up 10 Million Joint Venture With Midea Pharma MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding CI
Sun-Novo Pharma Logs 49.8% Jump in 2022 Profit MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sun-Novo Pharmaceutical Purchases Azilsartan Tablets’ Marketing Rights For $5 Million MT
Beijing Sun-Novo Gets Regulatory Approval in China For Anti-Dermatitis Cream MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. agreed to acquire Beijing Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership), Liu Yujing and other shareholders. CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(SHSE:688621) added to Shanghai Stock Exchange Composite Index CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(SHSE:688621) added to Shanghai Stock Exchange A Share Index CI
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Nanjing Heron Pharmaceutical Science and Technology Co.,LTD announced that it expects to receive CNY 20.000024 million in funding from Beijing Sun-Novo Pharmaceutical Research Co., Ltd. CI
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
More charts
Beijing Sun Novo Pharmaceutical Research Co Ltd is a China-based company that provides research and development outsourcing services for pharmaceutical companies. The Company's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The Company mainly conducts its businesses in the domestic market.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
57.69
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688621 Stock
  4. News Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
  5. Sun-Novo Pharma Unit Gets Drug Regulator's Certification for Desmopressin Injection